https://hifibio-com.agentsite.network/index.html 2026-07-26 daily 0.9 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-phase-1-clinical-trial-data-for-two-novel-immuno-oncology-antibodies-at-the-2024-annual-congress-of-the-european-society-for-medical-oncology.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/partnering/partnerships/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/sebastian-amigorena-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/phase-i-study-of-hfb200301-a-first-in-class-tnfr2-agonist-monoclonal-antibody-in-patients-with-solid-tumors-selected-via-drug-intelligent-science-dis.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2025/06/focis-2025-poster_hfb202501_clean-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-submits-ind-application-for-fully-human-sars-cov-2-neutralizing-antibody-for-the-treatment-of-covid-19-patients.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/robert-andtbacka-md-cm-joins-hifibio-therapeutics-as-chief-medical-officer.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-is-recognized-as-an-innovative-start-up-company-by-french-president-francois-hollande-at-the-inauguration-of-the-institute-pierre-gilles-de-gennes.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-preclinical-data-for-a-novel-immunology-antibody-at-the-2025-annual-meeting-of-the-clinical-immunology-society.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-showcase-dis-enabled-translational-insights-from-ongoing-phase-1-clinical-trials-for-two-novel-immuno-oncology-antibodies-at-the-2024-annual-meeting-of-the-society-for-im.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/programs/hfb3024/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/ey-announces-liang-schweizer-of-hifibio-therapeutics-as-an-entrepreneur-of-the-year-2024-new-england-award-winner.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibios-next-generation-antibody-discovery-platform-to-be-presented-by-pfizer-inc-at-pegs-europe-2015.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-to-present-platform-at-next-generation-antibodies-conference.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/phase-i-dose-escalation-trial-of-the-first-in-class-tnfr2-agonist-monoclonal-antibody-hfb200301-in-monotherapy-and-in-combination-with-tislelizumab-an-anti-pd-1-monoclonal-antibody-in-adult-patien.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb301001.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/dis-aacr-2022-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/yun-yueh-lu-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/programs/hfb301001/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/fierce-biotech-names-hifibio-therapeutics-a-fierce-15-biotech-company-of-2023.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb301001-aacr-2020-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/clinical-programs/hfb200603/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/peter-ho-md-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/fibrogen-and-hifibio-announce-transformative-partnership-to-advance-next-generation-therapies-for-patients-with-cancer-and-autoimmune-disease.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/victa-biotherapeutics-appoints-donald-w-kufe-to-board-of-directors.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200301.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-ceo-liang-schweizer-interviewed-by-life-science-success-podcast.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/fred-dom-2/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/09/hfb200301-esmo-2024-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/zixuan-pang-ph-d/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-and-collaborators-publish-single-cell-microfluidics-work-in-nature-biotechnology.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/integrating-public-single-cell-transcriptomics-and-patient-profiles-to-guide-clinical-development.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/pkpd-model-aacr-2024-poster-final-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-preclinical-data-of-three-leading-ii-programs-at-the-2025-annual-meeting-of-the-federation-of-clinical-immunology-societies.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2025/05/hfb1002-cis-poster-2025-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/high-throughput-functional-screening-for-next-generation-cancer-immunotherapy-using-droplet-based-microfluidics.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/biotechs-build-on-single-cell-analytics-for-drug-research-and-development-as-human-cell-atlas-is-mapped.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/innovation-drug-discovery-today-paper-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/drug-intelligence-science-dis-a-cutting-edge-translational-platform-by-hifibio-therapeutics-featured-in-drug-discovery-today.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-ceo-liang-schweizer-named-one-of-the-worlds-top-female-founders.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/mechanism-of-action-and-biomarker-strategy-for-hfb200301-an-anti-tnfr2-agonist-antibody-for-the-treatment-of-cancer.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb301001-poster-asco-2024-final-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/celligo-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-to-reverse-immune-suppression-in-the-tumor-microenvironment-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/clinical-approach-and-biomarker-strategy-for-hfb301001-a-novel-ox40-agonistic-antibody-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-trial-in-progress-poster-for-hfb301001-at-2022-esmo-congress.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/model-informed-dose-optimization-of-hfb200301-a-tnfr2-agonist-monoclonal-antibody-in-monotherapy-and-in-combination-with-the-anti-pd-1-tislelizumab-in-patients-with-advanced-solid-tumors.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/clinical-programs/hfb200301/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/peptalk/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-first-patient-first-visit-for-the-evaluation-of-hfb200301-in-combination-with-tislelizumab-in-patients-with-dis-selected-advanced-solid-tumors.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-presents-three-novel-immuno-oncology-programs-at-2020-aacr-virtual-annual-meeting-ii.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/going-global-insights-on-the-advantages-of-biotech-globalization-published-in-drug-discovery-today-from-hifibio-therapeutics.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/kite-and-hifibio-therapeutics-announce-a-research-collaboration-to-develop-technology-for-the-potential-discovery-of-neoantigen-reactive-t-cell-receptors-tcrs-for-the-treatment-of-cancer.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/science/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-oral-presentation-at-2023-american-association-for-cancer-research-aacr-annual-meeting.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-sas-announces-participation-in-next-generation-antibody-therapeutics-session-along-with-adimab-f-star-and-innovative-targeting-solutions-at-biointernational-2016-in-san-francisco-usa-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-contributes-to-covic-led-analysis-on-the-identification-of-distinct-epitope-communities-among-sars-cov-2-spike-antibodies-efficacious-against-variants-of-concern.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/deepak-rao-md-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/drug-intelligence-science-dis-pioneering-a-high-resolution-translational-platform-to-enhance-the-probability-of-success-for-drug-discovery-and-development-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/mechanism-of-action-and-biomarker-strategy-for-hfb200301-an-anti-tnfr2-agonist-antibody-for-the-treatment-of-cancer-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-progress-on-four-novel-immunotherapy-programs-at-aacr-2021.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/join-us/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2025/06/focis-2025-poster_hfb200604_clean-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-secures-37-5-million-series-b-financing-to-accelerate-pipeline-of-novel-antibody-drugs-to-treat-cancer-and-autoimmune-disorders.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-theraputics-aquires-h-immune-therapeutics/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/clinical-programs/hfb301001/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-for-the-treatment-of-aml-and-other-cancers.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-receives-approval-from-chinese-nmpa-for-ind-application-for-hfb200301-an-innovative-anti-tumor-monoclonal-antibody.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/peter-taylor-ma-phd-frcp-frcpe/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-presents-novel-approach-to-patient-stratification-demonstrating-dis-single-cell-platform-at-2020-aacr-tumor-heterogeneity-conference.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-ceo-liang-schweizer-sits-down-with-nyse-floor-talk-on-how-hifibio-is-using-ai-to-transform-drug-development.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb200603-a-novel-anti-btla-monoclonal-antibody-that-provides-therapeutic-potential-for-immune-escape-and-synergizes-with-anti-pd-1-treatment-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2025/06/focis-2025-poster_hfb302401_clean-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/phase-i-study-of-hfb301001-a-novel-ox40-agonist-monoclonal-antibody-in-patients-with-solid-tumors-selected-via-drug-intelligence-science-dis.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/dis-aacr-2024-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/safety-tolerability-pharmacokinetics-and-immunogenicity-of-an-anti-sars-cov-2-monoclonal-antibody-hfb30132a-after-single-dose-intravenous-administration-in-healthy-chinese-subjects-a-phase-1-rand.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/andrew-griffiths-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/drug-discovery-today/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-ceo-liang-schweizer-receives-2020-extraordinary-women-advancing-healthcare-award.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/application-of-hifibio-drug-intelligence-science-dis-translational-platform-to-guide-the-clinical-development-of-hfb200604-a-phase-i-btla-agonist-monoclonal-antibody.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/sample-page/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-unveils-several-novel-antibodies-showing-promise-to-be-precision-immunotherapies-for-cancer-patients.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2025/10/hfb200603-esmo-2025-poster_final-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/programs/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/drug-intelligence-science-dis-pioneering-a-high-resolution-translational-platform-to-enhance-the-probability-of-success-for-drug-discovery-and-development.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb101110-aacr-2022-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-sas-achieves-milestone-in-antibody-research-collaboration-with-pfizer-inc.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/predictive-and-generative-ai-to-guide-the-clinical-development-of-hfb200301-a-first-in-class-tnfr2-agonist-drug-intelligence-science-dis.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/phase-i-dose-escalation-study-of-hfb200603-a-best-in-class-btla-antagonist-monoclonal-antibody-in-monotherapy-and-incombination-with-the-anti-pd-1-mab-tislelizumab-in-adult-patients-with-advanced-sol.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-ceo-liang-schweizer-interviewed-by-lioness-magazine.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/droplet-screening-science-advances-paper-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-updated-phase-1-clinical-data-of-two-immuno-oncology-programs-at-the-2025-annual-meeting-of-the-european-society-for-medical-oncology-esmo.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/utilizing-drug-intelligence-science-dis-for-tumor-type-selection-and-molecular-characterization-of-hfb200603-a-best-in-class-b-and-t-lymphocyte-attenuator-btla-monoclonal-antagonist.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/targeting-regulatory-t-cells-with-hfb101110-a-novel-anti-human-ccr8-antibody-for-the-treatment-of-solid-tumors.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/global-or-local-the-future-of-biotech-publication-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/single-cell-deep-phenotyping-nature-biotechnology-paper-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/high-throughput-single-cell-activity-based-screening-and-sequencing-of-antibodies-using-droplet-microfluidics-2-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/targeting-regulatory-t-cells-with-hfb101110-a-novel-anti-human-ccr8-antibody-for-the-treatment-of-solid-tumors-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb301001-esmo-2022-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/scientific-advisory-board/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-phase-1-clinical-trial-data-for-two-novel-immuno-oncology-agonists-at-the-2024-annual-meeting-of-the-american-society-of-clinical-oncology.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/a-phase-i-monotherapy-dose-escalation-study-of-hfb301001-a-novel-next-generation-ox40-agonist-monoclonal-antibody-in-adult-patients-with-advanced-solid-tumors.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/discovery-and-characterization-of-novel-tnfr2-antibodies-to-modulate-t-cell-activities-in-immunosuppressive-environment-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/a-novel-biparatopic-klrg1-antibody-selectively-depletes-effector-memory-cd8-t-cells-for-autoimmune-disease-treatment.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/pipeline-overview/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-presents-two-posters-at-the-2024-american-association-for-cancer-research-annual-meeting.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb200301-asco-2022-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-completes-first-cohort-of-a-phase-i-study-of-its-sars-cov-2-neutralizing-antibody-for-the-treatment-and-prevention-of-covid-19.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/disclaimer/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/timothy-miller-msc/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/mj-kim/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-clinical-trial-supply-agreement-to-evaluate-hfb200603-in-combination-with-tislelizumab-in-patients-with-dis-selected-advanced-solid-tumors-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-and-gustave-roussy-researchers-demonstrate-the-contribution-of-galectin-9-gal-9-in-tumor-immune-escape.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-ceo-liang-schweizer-interviewed-by-pharmaboardroom-and-genialis-podcast.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/a-sars-cov-2-neutralizing-antibody-with-extensive-spike-binding-coverage-and-modified-for-optimal-therapeutic-outcomes.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb200301-aacr-2020-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/marco-londei-md/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/kite-and-hifibio-therapeutics-partner-to-discover-novel-targets-and-antibodies-against-acute-myeloid-leukemia.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/clinical-approach-and-biomarker-strategy-for-hfb301001-a-novel-ox40-agonistic-antibody.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/privacy-policy/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/scientific-founders/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb301001-a-novel-ox40-agonistic-antibody-with-a-unique-pharmacological-profile-and-innovative-biomarker-strategy-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/robert-nicol-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/dis-drug-intelligence-today-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/nature-biotechnology/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/discovery-and-characterization-of-novel-tnfr2-antibodies-to-modulate-t-cell-activities-in-immunosuppressive-environment.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-collaborates-with-institut-gustave-roussy-and-france-2030-initiative-to-pioneer-personalized-immunotherapies.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/alexandre-grassin-2/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/lynn-yang/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/single-cell-deep-phenotyping-of-igg-secreting-cells-for-high-resolution-immune-monitoring.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/helmuth-van-es-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/optimization-of-t-cell-co-stimulatory-agonists-a-semi-mechanistic-pkpd-model-integrating-drug-properties-and-tumor-immune-interactions.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-sas-to-present-advances-in-functional-therapeutic-antibody-discovery-with-two-talks-at-human-antibodies-and-hybridomas-conference-to-be-held-in-belfast-northern-ireland-wednesday-november-9.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/droplet-screening-nature-biotechnology-paper-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/antibody-discovery-by-deep-mining-of-immune-repertoires-a-demonstration-of-the-hifibio-celligo-platform-versatility-and-robustness-with-tetanus-toxoid-antigen-as-a-case-study.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/company-overview/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-sas-to-present-advances-in-functional-therapeutic-antibody-discovery-at-the-european-antibody-congress-on-tuesday-november-15-2016.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/gal_9_nature_scientific_reports_paper-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb200301-poster-asco-2024-final-version-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/guiding-principles-of-value-creation-through-collaborative-innovation-in-pharmaceutical-research.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/bradley-bernstein-md-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-closes-67-million-series-c-financing-to-build-on-recent-success-and-advance-pipeline-of-novel-antibody-drugs-for-cancer-and-autoimmune-disorders.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/antibody-discovery-by-deep-mining-of-immune-repertoires.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-for-the-treatment-of-aml-and-other-cancers-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb200603-a-novel-anti-btla-monoclonal-antibody-that-provides-therapeutic-potential-for-immune-escape-and-synergizes-with-anti-pd-1-treatment.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-collaborates-with-coronavirus-immunotherapy-consortium-in-the-fight-against-covid-19.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-publication-in-nature-communications-on-its-sars-cov-2-neutralizing-monoclonal-antibody.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-at-2024-american-association-for-cancer-research-annual-meeting.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/leslie-kean-md-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/programs/hfb200301/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/evaluation-of-hvem-and-pd-l1-expression-profile-in-tumors-as-potential-predictive-biomarkers-forhfb200603-a-btla-antagonist-as-monotherapy-and-in-combination-with-tislelizumab.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/discovery-and-characterization-of-a-novel-anti-human-cxcr5-antibody-for-the-treatment-of-b-cell-lymphomas.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/11/hfb200301-sitc-2024-final-1-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/leadership/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/high-throughput-single-cell-chip-seq-identifies-heterogeneity-of-chromatin-states-in-breast-cancer.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200603.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-receives-recognition-as-one-of-biocentury-innovations.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-and-leading-academic-institutions-demonstrate-breakthrough-single-cell-approach-for-novel-biomarker-discovery-to-combat-cancer.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/david-weitz-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/11/hfb200603-sitc-2024-final-1-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/ceo-liang-schweizer-sits-with-nasdaq-to-share-hifibio-therapeutics-mission-to-unlock-the-curative-powers-of-the-immune-system.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/ey-announces-liang-schweizer-of-hifibio-therapeutics-as-an-entrepreneur-of-the-year-2024-new-england-award-finalist.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/serial-transplantation-unmasks-galectin-e2-80-909-contribution-to-tumor-immune-escape-in-the-mb49-murine-model.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-clinical-trial-supply-agreement-to-evaluate-hfb200301-in-combination-with-tislelizumab-in-patients-with-dis-selected-advanced-solid-tumors.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/clinical-programs/hfb200604/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/michael-croft-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-the-appointment-of-leading-ii-experts-to-its-scientific-advisory-board.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/contact/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-receives-grant-to-research-long-covid-and-me-cfs-in-collaboration-with-umass-chan-medical-school.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb202501-a-novel-anti-pd-1-antibody-with-enhanced-effector-functions-for-precision-depletion-of-pathogenic-t-cells-in-autoimmune-diseases.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-drug-intelligence-science-dis-platform-wins-ai-innovation-of-the-year-in-2023-biotech-breakthrough-awards.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-and-vikas-sukhatme-join-forces-to-discover-and-develop-novel-antibody-treatments-for-cancer.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-closes-75-million-series-d-financing-to-accelerate-pipeline-with-two-lead-immuno-oncology-programs-and-validate-its-dis-approach-in-the-clinic.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/melissa-harney/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/about/board-of-directors/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb301001-a-novel-ox40-agonistic-antibody-with-a-unique-pharmacological-profile-and-innovative-biomarker-strategy.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/defining-variant-resistant-epitopes-targeted-by-sars-cov-2-antibodies-a-global-consortium-study.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-establishes-world-class-scientific-advisory-board.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/discovery-of-predictive-biomarkers-of-response-to-t-cell-targeting-biologics-using-ex-vivo-single-cell-profiling-coupled-with-tcr-clonotype-characterization-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-receives-fda-clearance-of-ind-application-for-hfb200604-a-best-in-class-btla-agonist-antibody-for-the-treatment-of-inflammatory-and-immunology-diseases.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/site-root.html 2026-07-26 monthly 1.0 https://hifibio-com.agentsite.network/content/hifibio-sas-to-report-results-from-the-first-fully-integrated-single-cell-antibody-discovery-platform-at-ibc-antibody-and-engineering-therapeutics-2015-conference.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hfb9-2-a-novel-galectin-9-neutralizing-antibody-to-reverse-immune-suppression-in-the-tumor-microenvironment.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/programs/hfb200604/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/partnering/open-innovation-hub/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/potential-predictive-biomarkers-of-clinical-benefit-from-emunkitug-hfb200301-in-combination-withtislelizumab-integrated-analysis-of-tumor-peripheral-blood-and-patient-treatment-history.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/cxcr5-as-a-therapeutic-target-in-autoimmune-diseases-insights-from-sjogrens-disease.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/cheryl-cui-ph-d/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/high-throughput-single-cell-activity-based-screening-and-sequencing-of-antibodies-using-droplet-microfluidics-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/discovery-of-predictive-biomarkers-of-response-to-t-cell-targeting-biologics-using-ex-vivo-single-cell-profiling-coupled-with-tcr-clonotype-characterization.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-partners-with-johnson-johnson-innovation/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/fred-dom/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb200603-aacr-2022-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/roshan-kumar-ph-d/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/09/hfb200603-esmo-2024-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/jerome-bibette-phd/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-presents-novel-approach-to-patient-stratification-demonstrating-dis-single-cell-platform-at-2020-aacr-tumor-heterogeneity-conference-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-publication-in-science-advances-of-its-high-throughput-functional-screening-for-next-generation-cancer-immunotherapy.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/pipeline/programs/hfb200603/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2024/07/hfb9-2-aacr-2020-poster-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/fibrogen-exercises-exclusive-license-option-for-hifibios-ccr8-program.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/jinping-gan-ph-d/index.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/discovery-and-characterization-of-a-novel-anti-human-cxcr5-antibody-for-the-treatment-of-b-cell-lymphomas-2.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/wp-content/uploads/2025/10/emunkitug-esmo-2025-poster_final-pdf.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-to-present-trial-in-progress-poster-for-hfb200301-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-ceo-liang-schweizer-shares-her-professional-journey-and-the-companys-pioneering-dis-approach-on-the-biotech2050-podcast.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-announces-three-presentations-at-2022-american-association-for-cancer-research-aacr-annual-meeting.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/hifibio-therapeutics-signs-multi-target-antibody-discovery-agreement-with-takeda.html 2026-07-26 monthly 0.8 https://hifibio-com.agentsite.network/content/high-throughput-single-cell-activity-based-screening-and-sequencing-of-antibodies-using-droplet-microfluidics.html 2026-07-26 monthly 0.8